Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 24 12:31PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-6.94 Insider Own1.81% Shs Outstand11.74M Perf Week-4.93%
Market Cap4.05M Forward P/E- EPS next Y-1.22 Insider Trans22.36% Shs Float11.58M Perf Month-4.96%
Income-8.89M PEG- EPS next Q- Inst Own0.56% Short Float1.03% Perf Quarter-8.97%
Sales0.00M P/S- EPS this Y85.85% Inst Trans-3.13% Short Ratio0.42 Perf Half Y-88.64%
Book/sh0.60 P/B0.57 EPS next Y-20.79% ROA-130.60% Short Interest0.12M Perf Year-96.27%
Cash/sh0.72 P/C0.48 EPS next 5Y- ROE-173.40% 52W Range0.31 - 10.87 Perf YTD-32.57%
Dividend Est.- P/FCF- EPS past 5Y-17.82% ROI-126.07% 52W High-96.84% Beta1.61
Dividend TTM- Quick Ratio4.84 Sales past 5Y0.00% Gross Margin- 52W Low9.65% ATR (14)0.03
Dividend Ex-Date- Current Ratio4.84 EPS Y/Y TTM61.05% Oper. Margin0.00% RSI (14)41.97 Volatility8.31% 7.07%
Employees2 Debt/Eq0.05 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price125.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q96.71% Payout- Rel Volume4.50 Prev Close0.33
Sales Surprise- EPS Surprise-1560.47% Sales Q/Q- Earnings- Avg Volume285.86K Price0.34
SMA20-7.30% SMA50-12.77% SMA200-85.11% Trades Volume631,926 Change4.83%
Today 08:12AM
May-22-24 07:00AM
May-09-24 01:55PM
May-02-24 02:33PM
08:31AM Loading…
Apr-30-24 08:31AM
Apr-29-24 09:00AM
Apr-23-24 07:31AM
Apr-15-24 08:31AM
Mar-06-24 07:00AM
Mar-05-24 08:31AM
Feb-20-24 08:01AM
Feb-05-24 08:30AM
Jan-29-24 08:00AM
08:01AM Loading…
Dec-11-23 08:01AM
Nov-30-23 04:01PM
Nov-28-23 08:43AM
Nov-27-23 09:40PM
Nov-20-23 09:27AM
Nov-17-23 07:00AM
Nov-07-23 08:20AM
Nov-06-23 05:35PM
Sep-22-23 08:30AM
Sep-21-23 09:35AM
Sep-11-23 11:51AM
Sep-08-23 02:30PM
Aug-15-23 10:20AM
08:47AM Loading…
Aug-09-23 08:47AM
Jul-20-23 08:00AM
Jul-10-23 08:47AM
Jul-06-23 08:30AM
May-15-23 08:47AM
May-09-23 07:15AM
May-02-23 04:05PM
Apr-27-23 09:50PM
Apr-13-23 08:47AM
Apr-12-23 10:30AM
Apr-10-23 08:47AM
Mar-28-23 08:47AM
Feb-28-23 09:45AM
Feb-15-23 07:11AM
Feb-13-23 04:15PM
Feb-10-23 07:17AM
Feb-08-23 07:11AM
Feb-06-23 07:00AM
Jan-31-23 10:41AM
Jan-17-23 11:29AM
Dec-12-22 05:39AM
Dec-01-22 08:47AM
Nov-22-22 06:30AM
Oct-18-22 08:47AM
Oct-06-22 08:47AM
Sep-14-22 08:47AM
Jul-08-22 08:17AM
Jul-04-22 03:35PM
Jun-27-22 08:27AM
Jun-13-22 09:06AM
Jun-02-22 08:47AM
May-05-22 08:47AM
Mar-02-22 08:37AM
Feb-16-22 09:40AM
Feb-14-22 09:04AM
Feb-11-22 07:15AM
Feb-01-22 09:40AM
Jan-26-22 08:30AM
Jan-14-22 04:00PM
Jan-13-22 11:05AM
Jan-11-22 07:55PM
Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. It also develops TH104, which is known to suppress chronic, debilitating pruritus or uncontrollable itching in PBC, a rare and orphan liver disease with no known cure. The company was founded on March 28, 2017 and is headquartered in Bridgewater, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MILBY RANDYCEODec 15 '23Buy0.5029,00014,587156,517Dec 18 10:04 AM
MILBY RANDYCEONov 30 '23Buy1.0010,00010,000127,517Dec 04 04:15 PM